Axerion Seeks New Answers in Spinal Cord Injury, Alzheimer's
Privately held Axerion Therapeutics Inc. hopes to translate two technologies exclusively licensed from Yale University into revolutionary therapeutics in a pair of indications spinal cord injury (SCI) and Alzheimer's disease (AD) that have bedeviled biotechs and big pharmas, alike.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST